MoBiTec, Germany, Closes Distribution Agreement for Transcreener® HTS System Platform with BellBrooks Labs, USA

March 14, 2012. -- BellBrook Labs, USA, is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. Their proprietary Transcreener® HTS Platform was developed to move more new targets into HTS more rapidly, and to streamline selectivity profiling within a target family. The partnership with MoBiTec, Germany, will enable BBL to offer their excellent products for High-Throughput Screening to scientists in Germany and adjacent countries.

Thousands of cellular reactions use nucleotides, either alone or in combination with other substrates. Enzymes in the purinome alone – those that use adenine and guanine nucleotides – comprise 13% of the coding capacity of the human genome. Of these, protein kinases have become highly validated drug targets, but lipid kinases, chaperone ATPases and GTPases as well as less obvious ATP-dependent enzymes such as Acetyl Co-A carboxylase are increasingly being targeted for therapeutic intervention.

BellBrook Labs’ Transcreener® HTS Assays is a universal, high-throughput screening platform for enzymes based on direct detection of nucleotide enzyme products with far red Fluorescence Intensity (FI), Fluorescence Polarization (FP) and Time Resolved-Fluorescence Resonance Energy Transfer (TR-FRET) readouts. Transcreener® assays enable scientists to screen more targets, both well characterized and emerging, faster and more efficiently.

Transcreener® is a universal assay method that can be used across entire families of nucleotide-dependent enzymes. Rather than using separate assays for a multitude of specific reaction products, such as phosphorylated proteins or lipids, a single nucleotide detection assay can be used for all of the enzymes that generate a common nucleotide product.

• Four assays cover thousands of target enzymes, including any kinase, ATPase, or GTPase.
• Direct detection means less chance for compound interference.
• Far Red FP, FI and TR-FRET readouts validated on major multimode readers.
• Single step, mix and read format with 8 hour deck and signal stability for easy automation.

About Bellbrook Labs
BellBrook Labs is dedicated to providing the pharmaceutical industry with enabling screening tools to accelerate the discovery of more effective therapies. As a small, R&D-driven company, BBL identifies areas where there is a strong need but a significant technical hurdle, and then BBL develops a solution. The company is focused on taking creative approaches to new product development and to continually improving the level of service provided to our customers. BellBrook is undergoing a big change with the launch of the first two iuvo™ products and the Invasion Assay Service in 2010. The company has built its reputation on Transcreener®, a biochemical assay platform, and with iuvo BBL is introducing completely new way to perform cellular assays.
www.bellbrooklabs.com

About MoBiTec GmbH
MoBiTec GmbH, Germany, is a privately held company, founded in 1987, that offers research tools for molecular and cell biology. Products include fluorescence reagents, kits and imaging tools, two- & one-hybrid systems for in vivo detection of molecular interactions, non-E. coli expression systems, cell transfection reagents and cell culture tools, immobilized and soluble enzymes, products for genomics and proteomics research, numerous antibodies and recombinant proteins, affinity chromatography products as well as general laboratory equipment. In parallel to its own product lines, MoBiTec distributes products from internationally renowned companies, e.g. Molecular Probes, Takara, AnaSpec, Echelon, MBL, MirusBio and EdgeBio, in Germany. MoBiTec products are distributed worldwide, in Germany from their home office, in other countries by distributors.
www.mobitec.com

MoBiTec GmbH
Arne Schulz
Lotzestr. 22a
37083 Goettingen, Germany
P: +49(0)551-707220
F: +49(=)551-7072222
info@mobitec.com
www.mobitec.com

This release was published on openPR.